Gilead reports positive HIV PrEP data for lenacapavir
Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...
Gilead, Vertex initiated as new big biotech buys at Citi
Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.
Gilead initiated with a Buy at Citi
Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...
Gilead reports results from pivotal Phase 3 PURPOSE 2 trial
Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...
The Pharma Letter2d
Lenacapavir efficacy shown in diverse range of patients
Gilead Sciences has announced new data from its pivotal Phase III PURPOSE 2 trial providing further details on the efficacy, ...
FiercePharma7d
Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit
Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...
Daily Maverick7d
How South Africa can help secure immediate, global access to HIV prevention drug lenacapavir
We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.
Nasdaq7d
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
Lenacapavir is being evaluated as a long-acting option in multiple ongoing and planned early and late-stage clinical studies in Gilead’s HIV prevention and treatment research program.
Gilead Sciences Tops Estimates in Q3
Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.
Morningstar7d
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
PURPOSE 2 is a pivotal Phase 3 trial evaluating twice-yearly lenacapavir, Gilead’s injectable HIV-1 capsid inhibitor for the investigational use of HIV prevention, among a broad and ...